首页> 美国卫生研究院文献>other >Efficacy and Safety of Individual Second-Generation vs First-Generation Antipsychotics in First Episode Psychosis: A Systematic Review and Meta-analysis
【2h】

Efficacy and Safety of Individual Second-Generation vs First-Generation Antipsychotics in First Episode Psychosis: A Systematic Review and Meta-analysis

机译:在第一集精神病中的个体第二代VS第一代抗精神病学的疗效和安全性:系统审查和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Because early treatment choice is critical in first episode schizophrenia-spectrum disorders (FES), this meta-analysis compared efficacy and tolerability of individual second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) in FES. We conducted systematic literature search (until 12/31/2010) and meta-analysis of acute, randomized trials with ≥1 FGA vs. SGA comparison; patients in their first episode of psychosis and diagnosed with schizophrenia-spectrum disorders; available data for psychopathology change, treatment response, treatment discontinuation, adverse effects, or cognition. Across 13 trials (n=2,509), olanzapine (7 trials) and amisulpride (1 trial) outperformed FGAs (haloperidol: 9/13 trials) in 9/13 and 8/13 efficacy outcomes, respectively, risperidone (8 trials) in 4/13, quetiapine (1 trial) in 3/13, and clozapine (2 trials) and ziprasidone (1 trial) in 1/13, each. Compared to FGAs, EPS-related outcomes were less frequent with olanzapine, risperidone and clozapine, but weight gain was greater with clozapine, olanzapine and risperidone. Pooled SGAs were similar to FGAs regarding total psychopathology change, depression, treatment response, and metabolic changes. SGAs significantly outperformed FGAs regarding lower treatment discontinuation, irrespective of cause, negative symptoms, global cognition, and less EPS and akathisia, while SGAs increased weight more (p’s<0.05-0.01). Results were not affected by FGA dose or publication bias, but industry-sponsored studies favored SGAs more than federally funded studies. To summarize, in FES, olanzapine, amisulpride and, less so, risperidone and quetiapine showed superior efficacy, greater treatment persistence and less EPS than FGAs. However, weight increase with olanzapine, risperidone and clozapine and metabolic changes with olanzapine were greater. Additional FES studies including broader-based SGAs and FGAs are needed.
机译:由于早期治疗选择对于首发精神分裂症-频谱疾病(FES)至关重要,因此该荟萃分析比较了FES中个别第二代抗精神病药(SGA)与第一代抗精神病药(FGA)的疗效和耐受性。我们进行了系统的文献检索(至2010年12月31日),并对≥1FGA与SGA进行比较的急性随机试验进行了荟萃分析;第一次精神病发作并被诊断为精神分裂症-频谱疾病的患者;有关心理病理变化,治疗反应,治疗中止,不良反应或认知的可用数据。在13项试验(n = 2,509)中,奥氮平(7项试验)和氨磺必利(1项试验)在9/13和8/13的疗效方面分别优于利培酮(8项试验)和FGA(氟哌啶醇:9/13项试验)。 / 13,喹硫平(1次试验)在3/13中,氯氮平(2次试验)和齐拉西酮(1次试验)在1/13中。与FGA相比,奥氮平,利培酮和氯氮平的EPS相关结局发生率较低,但氯氮平,奥氮平和利培酮的体重增加更大。在总的精神病理学变化,抑郁,治疗反应和代谢变化方面,合并的SGA与FGA相似。不论原因,阴性症状,整体认知以及更少的EPS和静坐不安,SGA都比FGA明显优于FGA,而SGA的体重增加更多(p <0.05-0.01)。结果不受FGA剂量或出版偏倚的影响,但是行业资助的研究比联邦政府资助的研究更偏爱SGA。总而言之,在FES中,与FGA相比,奥氮平,氨磺必利,以及更少的是利培酮和喹硫平显示出更高的疗效,更大的治疗持久性和更低的EPS。但是,奥氮平,利培酮和氯氮平的体重增加以及奥氮平的代谢变化更大。需要进行其他FES研究,包括范围更广的SGA和FGA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号